Business Context and Reporting Period
Tvardi Therapeutics, Inc. (TVRD), a Delaware corporation, filed this Form 8-K on July 17, 2026. The report details an amendment to its existing Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, increasing the capacity of its at-the-market (ATM) offering program.
Key Financial Metrics
- ATM Program Capacity Increase: The company increased its offering program to allow for the issuance of up to $9,689,765 in additional common stock.
- Recent Sales Activity: In the 12-month period ending July 17, 2026, the company sold 3,110,769 shares for approximately $11.0 million in gross proceeds.
- Public Float: The aggregate market value of common stock held by non-affiliates is $62,208,945, based on 12,441,789 shares.
- Stock Price Reference: Calculations were based on a closing price of $5.00 per share on July 8, 2026.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or specific debt levels.
Material Changes
The primary material change is the expansion of the company's ability to raise capital through its ATM program. Previously, the program was established under a shelf registration statement effective May 12, 2026, with an aggregate offering amount of up to $12.5 million. The July 17, 2026, prospectus supplement amends this to add $9,689,765 in capacity. The filing notes that no additional stock will be sold under the original prospectus following this supplement.
Outlook, Risks, and Management Commentary
The filing indicates the company is subject to General Instruction I.B.6 of Form S-3 (the "baby shelf" rule), which limits the amount of securities that can be sold under the registration statement based on the public float. The company has engaged Cooley LLP to provide a legal opinion on the validity of the additional shares, which is filed as an exhibit. The document includes standard disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the total remaining capacity under the amended ATM program ($9,689,765) and the timeline for potential sales.
- Confirm the current share count and dilution impact of the 3,110,769 shares sold in the prior 12 months.
- Review the "baby shelf" rule constraints to understand if the $62.2 million public float limits future fundraising under this specific registration.
- Check subsequent filings for actual execution of sales under the new $9.7 million capacity.